China Healthcare - Telltales
Healthcare demand in China is an overwhelming challenge - stretched to the limit by the expectations of a newly empowered middle class and pressured by desperate, impoverished and indebted families
Cancer
China Biotech - Coming of age?
To live up to the challenge and address the chronic diseases afflicting the population, biotech in China is committed for the long haul - R&D outcomes remain fickle and international license agreements get caught up in geopolitics
China - The rising tide of chronic diseases
Accounting for 80% of China’s 10.3 million annual deaths (2005 data), chronic diseases such as cancer, diabetes, cardiovascular or respiratory diseases, will become a growing burden on the population and cause severe economic loss
Will gene therapies become affordable ?
With a small number of facilities in the US, the logistics of individual treatment – and their length – are likely to limit patient access and the pricing structures raise issues with vast implications for insurers and patients alike
Immunotherapy by adaptive cell transfer (ACT) - CAR-T
The foundations of cancer treatment have been surgery, chemotherapy, radiation therapy and targeted therapies homing in on specific molecular changes seen primarily in cancer cells